secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001730430-26-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M
--------------------------------------------------------------------------------

- ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.
- Net income $14.2M Q4, $59.0M FY 2025 vs net loss of $8.9M/$43.2M in prior-year periods.
- Cash, cash equivalents & short-term investments $414.1M, no debt, up from $243.6M.
- 2026 ARCALYST revenue guidance $900-$920M; company expects positive annual cash flow from operations.
- KPL-387 Phase 2/3 recurrent pericarditis data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000014/0001730430-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000014/knsa-20260224x8k.htm
  HTML page:      https://secwatch.observer/filing/0001730430-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer